Dendritic Cell-Targeted Liposomes for Cancer Immunotherapy via Inhibition of Aryl Hydrocarbon Receptor

Strategic Insights -

Researchers at the Institute of Biomedical Sciences have discovered a novel approach to cancer immunotherapy using dendritic cell-targeted liposomes. The study, published in the Journal of Nanobiotechnology, reveals that inhibiting the aryl hydrocarbon receptor (AhR) in dendritic cells enhances the production of IL-12 and IFN-g, promoting tumor-killing activity. This breakthrough has significant implications for the development of more effective cancer treatments.

Key Takeaways:

  • The study identified a CD11c-targeting peptide (SP65) with high specificity for dendritic cells using phage display.
  • SP65-functionalized liposomes showed enhanced drug uptake and selectivity for dendritic cells in vitro and in vivo.
  • Incorporating the AhR inhibitor CH223191, the researchers developed SP65-lipo-CH, which promoted IL-12 secretion in dendritic cells.
  • Co-culturing natural killer cells with SP65-lipo-CH-pretreated dendritic cells increased IFN-g production and tumor-killing activity.
  • In MC38 and metastatic LLC mouse models, SP65-lipo-CH alone suppressed tumor growth and prolonged survival.
  • Dendritic cell-targeted liposomes represent a promising strategy for cancer immunotherapy.
  • Specific interaction between SP65 and CD11c transports CH223191 to dendritic cells, inhibiting AhR function.
  • Inhibition of AhR promotes IL-12 and IFN-g production in dendritic cells and natural killer cells, respectively.
  • The study provides a novel approach to targeting dendritic cells for cancer therapy.

Statistics:

  • 23(1):683 is the journal volume and page number of the study.
  • 115 is the zip code of the Institute of Biomedical Sciences in Taipei, Taiwan.
  • 2025 is the year the study was published.
  • 4 Crinan St, London N1 9XW, England is the address of BioMed Central.
  • 28 is the day of the month the news article was published.

Sources:

  • "Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor" (Journal of Nanobiotechnology, 2025;23(1):683)
  • Chen-Yun Yeh, et al. (Institute of Biomedical Sciences, Academia Sinica)
  • BioMed Central (www.biomedcentral.com)
  • Journal of Nanobiotechnology (www.jnanobiotechnology.com)